Clinical DiabetesPub Date : 2024-01-01Epub Date: 2024-04-15DOI: 10.2337/cd24-a014
{"title":"Section 14: Children and Adolescents.","authors":"","doi":"10.2337/cd24-a014","DOIUrl":"https://doi.org/10.2337/cd24-a014","url":null,"abstract":"","PeriodicalId":39894,"journal":{"name":"Clinical Diabetes","volume":"42 2","pages":"218-219"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11040030/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140870142","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Clinical DiabetesPub Date : 2024-01-01Epub Date: 2024-04-15DOI: 10.2337/cd24-a008
{"title":"Section 8: Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes.","authors":"","doi":"10.2337/cd24-a008","DOIUrl":"https://doi.org/10.2337/cd24-a008","url":null,"abstract":"","PeriodicalId":39894,"journal":{"name":"Clinical Diabetes","volume":"42 2","pages":"204-205"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11040025/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140867696","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Clinical DiabetesPub Date : 2024-01-01Epub Date: 2024-04-15DOI: 10.2337/cd24-aint
{"title":"Introduction: <i>Standards of Care in Diabetes-2024</i> Abridged for Primary Care Professionals.","authors":"","doi":"10.2337/cd24-aint","DOIUrl":"https://doi.org/10.2337/cd24-aint","url":null,"abstract":"","PeriodicalId":39894,"journal":{"name":"Clinical Diabetes","volume":"42 2","pages":"181"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11040011/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140858336","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Clinical DiabetesPub Date : 2024-01-01Epub Date: 2023-08-22DOI: 10.2337/cd22-0118
Carolina Solis-Herrera, Michael P Kane, Curtis Triplitt
{"title":"Current Understanding of Sodium N-(8-[2-Hydroxylbenzoyl] Amino) Caprylate (SNAC) as an Absorption Enhancer: The Oral Semaglutide Experience.","authors":"Carolina Solis-Herrera, Michael P Kane, Curtis Triplitt","doi":"10.2337/cd22-0118","DOIUrl":"10.2337/cd22-0118","url":null,"abstract":"<p><p>Oral administration of peptide therapeutics faces challenges because of the distinct environment of the gastrointestinal tract. An oral formulation of semaglutide, a glucagon-like peptide 1 receptor agonist, was approved by the U.S. Food and Drug Administration in 2019 as a peptide therapy for the treatment of type 2 diabetes. Oral semaglutide uses sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC) technology to enhance the absorption of semaglutide in the stomach and protect it from degradation by gastric enzymes. This article presents a summary of studies investigating SNAC technology as an absorption enhancer for a number of molecules and, in particular, explores how SNAC, once coformulated with oral semaglutide, facilitates increased absorption and bioavailability. Practical advice and dispensing information for pharmacists is also provided.</p>","PeriodicalId":39894,"journal":{"name":"Clinical Diabetes","volume":" ","pages":"74-86"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10788673/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42572058","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Clinical DiabetesPub Date : 2024-01-01Epub Date: 2024-04-15DOI: 10.2337/cd24-a004
{"title":"Section 4: Comprehensive Medical Evaluation and Assessment of Comorbidities.","authors":"","doi":"10.2337/cd24-a004","DOIUrl":"https://doi.org/10.2337/cd24-a004","url":null,"abstract":"","PeriodicalId":39894,"journal":{"name":"Clinical Diabetes","volume":"42 2","pages":"189-192"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11040026/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140866816","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Clinical DiabetesPub Date : 2024-01-01Epub Date: 2024-01-15DOI: 10.2337/cd23-0095
Jay H Shubrook
{"title":"Improving Care for People With Type 1 Diabetes.","authors":"Jay H Shubrook","doi":"10.2337/cd23-0095","DOIUrl":"10.2337/cd23-0095","url":null,"abstract":"","PeriodicalId":39894,"journal":{"name":"Clinical Diabetes","volume":"42 1","pages":"10-11"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10788669/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139479510","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Clinical DiabetesPub Date : 2024-01-01Epub Date: 2024-04-15DOI: 10.2337/cd24-a015
{"title":"Section 15: Management of Diabetes in Pregnancy.","authors":"","doi":"10.2337/cd24-a015","DOIUrl":"https://doi.org/10.2337/cd24-a015","url":null,"abstract":"","PeriodicalId":39894,"journal":{"name":"Clinical Diabetes","volume":"42 2","pages":"220-221"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11040023/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140866815","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Clinical DiabetesPub Date : 2024-01-01Epub Date: 2023-08-25DOI: 10.2337/cd22-0124
Terin T Sytsma, Laura S Greenlund, Karen M Fischer, Rozalina G McCoy
{"title":"Impact of Intra-Articular Corticosteroid Injection on Glycemic Control: A Population-Based Cohort Study.","authors":"Terin T Sytsma, Laura S Greenlund, Karen M Fischer, Rozalina G McCoy","doi":"10.2337/cd22-0124","DOIUrl":"10.2337/cd22-0124","url":null,"abstract":"<p><p>This retrospective cohort study investigated the longer-term hyperglycemic effects of intra-articular corticosteroid (IACS) administration by evaluating changes in A1C after large joint IACS injection. Among 1,169 patients (mean age 66.1 ± 12.2 years, 52.8% female), 184 (15.7%) experienced a greater-than-expected rise in A1C (actual A1C ≥0.5% above predicted) after IACS. Greater-than-expected rise in A1C was associated solely with baseline A1C (odds ratio [OR] 1.84, 95% CI 1.08-3.13 for baseline A1C of 7.0-8.0% compared with <7.0% and OR 4.79, 95% CI 2.83-8.14 for baseline A1C >8.0% compared with <7.0%). Although most patients do not experience an increase in A1C after IACS, clinicians should counsel patients with suboptimally controlled diabetes about risks of further hyperglycemia after IACS administration.</p>","PeriodicalId":39894,"journal":{"name":"Clinical Diabetes","volume":" ","pages":"96-103"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10788672/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43587755","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}